Gaffin David Joseph sold $83K of ALKS
Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $41.03 on 2026-10-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to move the stock significantly, but it adds to the cumulative insider activity record.
Market read
A routine insider sale with limited price impact; primarily of interest to short‑term traders monitoring insider activity.
What to watch
The 10b5-1 plan suggests pre‑planned execution, reducing the likelihood of insider information concerns.
Background
SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.
Ticker impact
EVP CLO sold 2,034 shares for $83,455 via a 10b5-1 plan, reducing holdings to 221,388 shares.
likely slight downward pressure as the market prices in the insider sell
The transaction size is small relative to market cap, but insider sales are often viewed negatively by investors.
Market effects
Minimal impact on the biotech/pharma sector; typical insider sales do not shift sector sentiment.
No regional effect; the filing is company‑specific.
Limited global relevance; only ALKS investors are directly affected.
Counterpoint
The sale could be a routine liquidity event and not indicative of negative fundamentals.
Key entities
- companyAlkermes plc.
Biopharmaceutical company listed on NASDAQ under ALKS.
- personDavid Joseph Gaffin
Executive Vice President and Chief Legal Officer of Alkermes.
